CD274 and breast cancer: It was recently observed that a combination of anti-PD-(L)1 and a MEK inhibitor (trametinib) yielded an increase in MHC class I and II expression, and of PD-L1 in vitro in human and murine mammary cancer cells, as well as in vivo in mice [71].